Artificial intelligence: Catalyzing a new era in pancreatic cancer cure
Cancer Letters · 2026
DOI: 10.1016/j.canlet.2026.218558 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Letters, 2026. Verfasst von Jun Wang und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, …. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Artificial Intelligence, Carcinoma, Pancreatic Ductal, Antineoplastic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 97 Literaturangaben. Gefördert von: Fundamental Research Funds for the Central Universities, Natural Science Foundation of Beijing Municipality, Peking Union Medical College Hospital.
Abstract (Originalsprache)
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal human cancers, mostly due to its insidious onset that consequently leads to diagnosis at advanced stages. The complex biology of PDAC limits effective therapeutic options, yet over 90% of cases harbor KRAS mutations, making it a compelling therapeutic target. KRAS had a notorious history of being "undruggable." Emerging novel inhibitors, however, have fundamentally shifted this paradigm by demonstrating the possibility of direct KRAS targeting. Although promising in preclinical efficacy, the clinical benefit of these inhibitors was frequently curtailed by rapid and heterogeneous resistance due to the intrinsic complexity of PDAC. Concurrently, building on structure-based drug discovery, artificial intelligence (AI) is now infusing this traditional workflow with dynamic and extensive enhancements. AI-enabled approaches in molecular biology-including high-accuracy protein structure prediction, large-scale virtual screening, and the uprising of generative molecular design-have accelerated the discovery of potent and selective molecular structures. Comprehensive hybrid models and quantum-level data processing enabled the exploration of previously latent chemical spaces, thereby creating more opportunities for the search for effective PDAC therapies. Discussions of progress in KRAS inhibitors and in AI drug discovery are rising but remain largely in parallel. As a result, this review aims to bridge these two exciting fields together. Through discussions of novel strategies to target KRAS in PDAC, emerging paradigms to address KRAS resistance in clinical trials, and current innovations in AI algorithms for molecule screening and design, we hope to underscore the unique challenges and prospects of leveraging artificial intelligence to accelerate the discovery of effective therapies for PDAC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China. Electronic address: wangj9669@gmail.com.
- Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China.
- Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China. Electronic address: zhangtaiping@pumch.cn.
- Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China. Electronic address: zhao8028@263.net.
Förderung
- Fundamental Research Funds for the Central Universities
- Natural Science Foundation of Beijing Municipality
- Peking Union Medical College Hospital
- National Key Research and Development Program of China
- Beijing Science and Technology Planning Project
- Peking Union Medical College
- National Natural Science Foundation of China
Zitieren
APA
Wang, J., Luo, W., Zhang, M., Wang, Y., Ye, L., Qiu, J. D., Liu, Y., Weng, G., Liu, T., Cao, Z., Yang, G., Huang, H., Xiao, J., You, L., Zhang, T., & Zhao, Y. (2026). Artificial intelligence: Catalyzing a new era in pancreatic cancer cure. Cancer Letters. https://doi.org/10.1016/j.canlet.2026.218558
Vancouver
Wang J, Luo W, Zhang M, Wang Y, Ye L, Qiu JD, et al. Artificial intelligence: Catalyzing a new era in pancreatic cancer cure. Cancer Letters. 2026. doi:10.1016/j.canlet.2026.218558
BibTeX
@article{Wang2026,
author = {Wang, Jun and Luo, Wenhao and Zhang, Menggang and Wang, Yuangyang and Ye, Liyuan and Qiu, Jiang Dong and Liu, Yueze and Weng, Guihu and Liu, Tao and Cao, Zhe and Yang, Gang and Huang, Hua and Xiao, Jianchun and You, Lei and Zhang, Taiping and Zhao, Yupei},
title = {Artificial intelligence: Catalyzing a new era in pancreatic cancer cure},
journal = {Cancer Letters},
year = {2026},
doi = {10.1016/j.canlet.2026.218558}
}
EUVIMED